New Data Help Size Up Novel Class Of SGLT-2 Inhibitors In Diabetes
Though probable class side effects of urinary tract and genital infections remain worrisome, SGLT-2 inhibitors nevertheless have potential as add-ons to multiple kinds of diabetes drugs, based on data released at the recent American Diabetes Association meeting
You may also be interested in...
The big pharma beats analysts' estimates for the third quarter, but all eyes are turned toward its pipeline as the Plavix patent expiry becomes a near-term reality.
The agency will ask its Endocrinologic and Metabolic Drugs Advisory Committee to weigh these "unexpected" safety findings despite a clean cardiovascular profile for Bristol-Myers Squibb/AstraZeneca's first-in-class diabetes drug.
As part of its ongoing effort to develop drugs for metabolic disease, Boehringer Ingelheim is gearing up for a filing within the next few months of its first diabetes drug - the DPP-4 inhibitor linagliptin